Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yup. I’ve been in this since Sept 2013. Averaged below .30. Didn’t think it would take 7 years to get to where we are today.. Wait.. where are we? I guess I’ll hold a little longer to find out.. -__-
The world is waiting Linda.... Time to deliver..
Dendreon went from $3 to $27 in April 2009, on news of their successful trial.
Use the same metric for NWBO on success $1 to $9 within a month on positive top line, compound that with a successful manufacturing scale up, approval chance in four countries, and a whole slew of combination trials upcoming. Double digits.
We “are prioritizing the development of several promising oncology candidates with the potential to improve the treatment of advanced cancers”
I wonder if Kevin Duffy learned about any potential cancer treatment improvements to Keytruda during his 7 month tenure at NWBO?
This site should update # shares shorted later today. Will we see 20 million+ legal shares short???
Speaking of shorts... NVCR breaking 100 reaching all time highs days before NWBO releases TLD. Coincidence? Large short on NVCR or put option play after positive NWBO data might be the way to go. I know Flipper will likely jump on this.
If NWBO previously locked and got the top line data in order to get late breaking abstract at SNO...
If data was bad they would have 3 days to report?
If data was positive they would be allowed more time to report?
......
Linda reiterates twice in a 5 minute presentation that the results of their 13 year phase 3 trial due end of September. Stay tuned.......
Place your final bets.....
Absolutely.
It is important that shareholders express their concerns in writing to the company. The more the better.
https://nwbio.com/contact-us-general/
Said the same thing to me.
https://nwbio.com/contact-us-general/
Please report through this link. Power in numbers.
Now they can potentially forego any additional raises before TLD if they begin exercising some of the warrants to raise cash needed..
"If some of the information that currently remains outstanding cannot be obtained by mid-June, the Company may consider proceeding with a “soft lock” of the data at that time, if arrangements can be made for the rest of the data to be included when it is obtained later."
^From June 2 PR
Looking like soft lock coming in next week or so that way they can get the statisticians started while the rest of the data continues to trickle in...
Just my opinion of course ;]
7 for me.
This 8k is also positive because of what it doesn't say. 10 days before data lock is supposed to occur they do not give any indication of delay... They also made it clear the late 10-q will not slow down progress.
When the company goes into data lock, we will hear about it. Bank on it.
You seem edgy today JR
When Woodford was buying on the open market and NWBO was around 11-12$ a share the company was valued slightly under a billion.
Phase V, AF, shorting, Ondra/Wolf, trial screening halt, trial continuing on for multiple years past deadline for OS and tail.... A lot has changed since then.
Would you prefer they instead used a manufacturing company that was in the pocket of big pharma? If so they likely never would have made it this far.
What may appear to be self dealing on the surface might very well have been the only way for a small biotech like NWBO to survive the length of DCVax-L trial despite relentless smear campaign and shorting.
Linda will not let her warrants expire worthless..
I bet her plan was to exercise them after announcing Data Lock at ASM. But then the coronavirus slowed everything down..
Wonder what Cognate will do because they have a serious chunk of warrants expiring as well.
Guess we will find out soon enough
A .2150 B .1799 hope I am wrong.
It seems we are at our 1.2 billion share count when fully diluted...
"665,078,150 shares outstanding prior to this transaction as of April 8, 2020."
"19,947,032 shares of Common Stock is being offered April 9."
(50% Warrants = 9,973,516)
"As of December 31, 2019, 359.5 million shares of our common stock are issuable upon exercise of outstanding warrants and 104.7 million shares of our common stock are issuable upon exercise of outstanding options."
That adds up to 1,159,198,698 shares fully diluted.
Other than today's raise, were other warrants or options given out after December 31 2019?
Guess the new raise announcement after hours... 2 million at 15 cents?
Are you able to log on using your control number and password yet?
They have repeatedly said they are not waiting on anything.
I don’t know how coronavirus will affect FDA timelines
So now the FDA has 30 days after the comment period ends to release a statement that in 30 days this guidance will go into effect.
Therefore we have less than 60 days until this guidance goes into effect.
I know NWBO states they aren’t waiting for anything, but this confluence of events looks pretty interesting... (ASM proxy, data lock soon, possible partnership, FDA guidance completed in 60 days, warrant expiry, unblinding, and then ASCO in ~70 days).
It seems there will be a nice little buildup toward TLD.
Added today.
Added today .1999
Shareholder Meeting:
BETHESDA, Md., February 18, 2020 - Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the 2019 Annual Shareholder’s Meeting will be held on April 18, 2020, at 1:00 pm in Washington, DC.
The Company encourages shareholders to attend what should be an interesting meeting. This announcement is being made to allow shareholders time to make necessary travel plans to come to Washington. The proxy information and other materials will be forwarded to shareholders in an official mailing at a later date.
The Company looks forward to seeing all who can attend.
Alpine/SEC caused the drop
According to DI, this date change still would have no bearing on when they do data lock and release top line.
Tom Mathies:
https://twitter.com/TomMathies
https://www.linkedin.com/in/tom-mathies-a790804/
Another NWBO basher over the years...
Who is he?
Anthony Schwartz:
https://twitter.com/aschwartzphd
https://www.linkedin.com/in/anthonyschwartzphd/
Avid basher and critic of NWBO on Twitter (mostly 2017 and 2018, jumping on the Adam Feuerstein bandwagon) is now CEO of an immunotherapy company!
The immunotherapy company is called Morphiex Biotherapeutics, website here:
http://morphiex.com ..... Anyone heard of it? 240 Newbury Street, 2nd Floor, Boston
Funny how conflicts of interest become more evident after length of time has passed.
Hank I heard the same in my last conversation.
They are moving as expeditiously as possible to data lock, and they are not waiting for conference, new FDA guidelines, etc. It will be out when it is out.
There is however, a very positive confluence of events happening that will be very positive for NWBO.
Hold tight.
I disagree. I think NWBO would welcome the influx of cash from warrant exercise after topline. Then they can have ample time to wait for the right price for the next deal.
All combined, those warrants estimated to provide ~70 million $$? Don't quote me on that number.
Last year ASM was Feb 2. They are required to have an ASM every year and must let shareholders know at least 10 days before the meeting date.
I wonder if they are waiting until they have something to talk about....
Added more shares today @ .1952, happy to get another good chunk under .20
Taken from Carlo Rago's Twitter:
"Interesting. DCVax-L protocol available for storing tumor tissue on VirtualTrials. I wonder how many patients were treated with DCVax-L under compassionate use in 2019. And what are the projections for 2020? How much revenue is expected?"
$NWBO $MRK $BMY
http://virtualtrials.com/pdf2018/dcvaxfreeze.pdf